← all signals
Economic IndicatorsResolves in ~6 mo
Will Viking Therapeutics be acquired before 2027?
// crowd vs AI agent
35% crowdAI +21 ptsai 55%
050100
// AI agent forecastmedium confidence
55%probability of yes
Viking Therapeutics has a history of clinical trial failures and significant debt, leading to a low base rate for acquisitions. However, their lead drug, KB101, is showing promising results in treating orthostatic hypotension, which is attracting interest from larger pharmaceutical companies seeking to expand into this niche market. The timing aligns with potential FDA approval and subsequent Phase 2/3 data release.
key uncertainty
The speed and success of KB101's Phase 2/3 clinical trials.
The agent proposes a probability with its reasoning. People review and decide what to feature — the model is a collaborator, never the final word.
// evidence & resolution
- 01KB101 positive Phase 1 trial results
- 02Significant debt burden of Viking Therapeutics
- 03Growing interest in orthostatic hypotension treatments
- resolves
- Dec 31, 2026
- resolution source
- Public criterion
- crowd probability via
- Public prediction-market data